Definium Therapeutics (DFTX) Other Non-Current Assets (2022 - 2026)
Definium Therapeutics (DFTX) reported Other Non-Current Assets of $812000.0 for Q1 2026, up 33.99% year-over-year from $606000.0 in Q1 2025, and down 5.8% quarter-over-quarter from $862000.0 in Q4 2025.
Definium Therapeutics (DFTX) Other Non-Current Assets (2022 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has 5 years of Other Non-Current Assets data on file, last reported at $812000.0 in Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $812000.0, up 33.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $812000.0 (up 33.99% YoY), and the FY2025 annual result was $862000.0, up 40.62% from the prior year.
- Other Non-Current Assets retreated to $812000.0 in Q1 2026 per DFTX's latest filing, from $862000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $1.2 million in Q2 2025 and troughed at $144000.0 in Q1 2024.
- A 5-year average of $552857.1 and a median of $513500.0 in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets sank 52.0% in 2024, then surged 320.83% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $331000.0 in 2022, then plunged by 32.33% to $224000.0 in 2023, then jumped by 173.66% to $613000.0 in 2024, then soared by 40.62% to $862000.0 in 2025, then declined by 5.8% to $812000.0 in 2026.
- Business Quant data shows DFTX's Other Non-Current Assets at $812000.0 in Q1 2026, $862000.0 in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Definium Therapeutics | 2.46 Bn | 2.09 Bn | - | 812,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 812,000.00 |
| Dec 31, 2025 | 862,000.00 |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 1.17 Mn |
| Mar 31, 2025 | 606,000.00 |
| Dec 31, 2024 | 613,000.00 |
| Sep 30, 2024 | 493,000.00 |
| Jun 30, 2024 | 534,000.00 |
| Mar 31, 2024 | 144,000.00 |
| Dec 31, 2023 | 224,000.00 |
| Sep 30, 2023 | 229,000.00 |
| Jun 30, 2023 | 268,000.00 |
| Mar 31, 2023 | 300,000.00 |
| Dec 31, 2022 | 331,000.00 |